Juan Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Juan Wang has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Bei Miao
Department of Gastroenterology, The Affiliated Hospital of Xuzhou Medical University, China
14 shared publications - Feiyue Zhang
Department of Gastroenterology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
14 shared publications - Jiajia Wang
Oncology Center, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
14 shared publications - Li Li
Department of Gastroenterology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
14 shared publications - Masami Yamamoto
Laboratory of Physiological Pathology, School of Veterinary Nursing and Technology, Nippon Veterinary and Life Science University, Tokyo, Japan
14 shared publications - Pengbo Zhang
Department of Gastrointestinal Surgery Affiliated Hospital of Xuzhou Medical University Xuzhou China
14 shared publications
Latest Publications
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from BFAR Promotes Neutrophil Infiltration and Immunosuppressive Reprogramming through the PRP19–YBX1 Axis to Induce Immune Evasion in Gastric Cancer
Supplementary Figure 2. BFAR drives gastrointestinal tumorigenesis
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from BFAR Promotes Neutrophil Infiltration and Immunosuppressive Reprogramming through the PRP19–YBX1 Axis to Induce Immune Evasion in Gastric Cancer
Supplementary Figure 2. BFAR drives gastrointestinal tumorigenesis
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from BFAR Promotes Neutrophil Infiltration and Immunosuppressive Reprogramming through the PRP19–YBX1 Axis to Induce Immune Evasion in Gastric Cancer
Supplementary Figure 6. BFAR is not ubiquitinated by PRP19
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from BFAR Promotes Neutrophil Infiltration and Immunosuppressive Reprogramming through the PRP19–YBX1 Axis to Induce Immune Evasion in Gastric Cancer
Supplementary Figure 6. BFAR is not ubiquitinated by PRP19
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from BFAR Promotes Neutrophil Infiltration and Immunosuppressive Reprogramming through the PRP19–YBX1 Axis to Induce Immune Evasion in Gastric Cancer
Supplementary Figure 3. Infiltration of macrophages and T cells is independent of BFAR
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from BFAR Promotes Neutrophil Infiltration and Immunosuppressive Reprogramming through the PRP19–YBX1 Axis to Induce Immune Evasion in Gastric Cancer
Supplementary Figure 3. Infiltration of macrophages and T cells is independent of BFAR
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from BFAR Promotes Neutrophil Infiltration and Immunosuppressive Reprogramming through the PRP19–YBX1 Axis to Induce Immune Evasion in Gastric Cancer
Supplementary Figure 4. Bfar knockdown restrains the neutrophil chemokines expressions
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from BFAR Promotes Neutrophil Infiltration and Immunosuppressive Reprogramming through the PRP19–YBX1 Axis to Induce Immune Evasion in Gastric Cancer
Supplementary Figure 4. Bfar knockdown restrains the neutrophil chemokines expressions
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from BFAR Promotes Neutrophil Infiltration and Immunosuppressive Reprogramming through the PRP19–YBX1 Axis to Induce Immune Evasion in Gastric Cancer
Primers used for real-time quantitative PCR
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from BFAR Promotes Neutrophil Infiltration and Immunosuppressive Reprogramming through the PRP19–YBX1 Axis to Induce Immune Evasion in Gastric Cancer
Primers used for real-time quantitative PCR
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Data from BFAR Promotes Neutrophil Infiltration and Immunosuppressive Reprogramming through the PRP19–YBX1 Axis to Induce Immune Evasion in Gastric Cancer
The immunosuppressive tumor microenvironment remains a major barrier to effective immunotherapy in gastric cancer. In this study, we identified the E3 ubiquitin ligase BFAR as a critical regulator of neutrophil-mediated immune evasion through the S100A8/A9–BFAR–PRP19–YBX1 signaling axis. Multiomics analyses revealed that BFAR is overexpressed in gastric cancer and correlates with poor prognosis. Functional studies demonstrated that BFAR knockdown suppressed tumor growth by reducing neutrophil infiltration and immunosuppressive reprogramming to restore CD8+ T-cell function. Mechanistically, BFAR mediated K48-linked ubiquitination and degradation of PRP19, leading to stabilization of the oncoprotein YBX1, which transcriptionally upregulated neutrophil-recruiting chemokines CXCL1/CXCL3. Infiltrating neutrophils secreted S100A8/A9, which activated NF-κB to induce BFAR expression in tumor cells and created a feed-forward loop that sustains an immunosuppressive tumor microenvironment. Furthermore, BFAR promoted neutrophil PD-L1 expression via GM-CSF, reinforcing T-cell exhaustion. Clinically, BFAR expression correlated with neutrophil infiltration and poor response to anti–PD-1 therapy, whereas its inhibition synergizes with immune checkpoint blockade in preclinical models. Our work unveils BFAR as a central orchestrator of neutrophil-driven immunosuppression and proposes targeting this axis to enhance immunotherapy efficacy in gastric cancer.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from BFAR Promotes Neutrophil Infiltration and Immunosuppressive Reprogramming through the PRP19–YBX1 Axis to Induce Immune Evasion in Gastric Cancer
The immunosuppressive tumor microenvironment remains a major barrier to effective immunotherapy in gastric cancer. In this study, we identified the E3 ubiquitin ligase BFAR as a critical regulator of neutrophil-mediated immune evasion through the S100A8/A9–BFAR–PRP19–YBX1 signaling axis. Multiomics analyses revealed that BFAR is overexpressed in gastric cancer and correlates with poor prognosis. Functional studies demonstrated that BFAR knockdown suppressed tumor growth by reducing neutrophil infiltration and immunosuppressive reprogramming to restore CD8+ T-cell function. Mechanistically, BFAR mediated K48-linked ubiquitination and degradation of PRP19, leading to stabilization of the oncoprotein YBX1, which transcriptionally upregulated neutrophil-recruiting chemokines CXCL1/CXCL3. Infiltrating neutrophils secreted S100A8/A9, which activated NF-κB to induce BFAR expression in tumor cells and created a feed-forward loop that sustains an immunosuppressive tumor microenvironment. Furthermore, BFAR promoted neutrophil PD-L1 expression via GM-CSF, reinforcing T-cell exhaustion. Clinically, BFAR expression correlated with neutrophil infiltration and poor response to anti–PD-1 therapy, whereas its inhibition synergizes with immune checkpoint blockade in preclinical models. Our work unveils BFAR as a central orchestrator of neutrophil-driven immunosuppression and proposes targeting this axis to enhance immunotherapy efficacy in gastric cancer.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from BFAR Promotes Neutrophil Infiltration and Immunosuppressive Reprogramming through the PRP19–YBX1 Axis to Induce Immune Evasion in Gastric Cancer
Supplementary Figure 8. BFAR is a inhibitory factor to anti-PD1 therapy
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from BFAR Promotes Neutrophil Infiltration and Immunosuppressive Reprogramming through the PRP19–YBX1 Axis to Induce Immune Evasion in Gastric Cancer
Supplementary Figure 8. BFAR is a inhibitory factor to anti-PD1 therapy
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from BFAR Promotes Neutrophil Infiltration and Immunosuppressive Reprogramming through the PRP19–YBX1 Axis to Induce Immune Evasion in Gastric Cancer
Sequences of shRNA/siRNA for specific gene knockdown
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from BFAR Promotes Neutrophil Infiltration and Immunosuppressive Reprogramming through the PRP19–YBX1 Axis to Induce Immune Evasion in Gastric Cancer
Sequences of shRNA/siRNA for specific gene knockdown
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from BFAR Promotes Neutrophil Infiltration and Immunosuppressive Reprogramming through the PRP19–YBX1 Axis to Induce Immune Evasion in Gastric Cancer
Supplementary Figure 5. BFAR induces exhaustion and inactivation of T cells dependent on its RING domain
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from BFAR Promotes Neutrophil Infiltration and Immunosuppressive Reprogramming through the PRP19–YBX1 Axis to Induce Immune Evasion in Gastric Cancer
Supplementary Figure 5. BFAR induces exhaustion and inactivation of T cells dependent on its RING domain